Effects of the changes between preand post-treatment 18F-FDG PET-CT volumetric parameters on overall survival in pleural mesothelioma

IF 0.3 Q4 ONCOLOGY Oncology in Clinical Practice Pub Date : 2023-05-29 DOI:10.5603/ocp.2023.0022
Faris Tüzün, S. Ebinç, M. Kaplan, İ. Kaplan, H. Kömek, Z. Oruç, Şadiye Kemal Tuzcu, B. Taşdemir
{"title":"Effects of the changes between preand post-treatment 18F-FDG PET-CT volumetric parameters on overall survival in pleural mesothelioma","authors":"Faris Tüzün, S. Ebinç, M. Kaplan, İ. Kaplan, H. Kömek, Z. Oruç, Şadiye Kemal Tuzcu, B. Taşdemir","doi":"10.5603/ocp.2023.0022","DOIUrl":null,"url":null,"abstract":"Introduction. This study aimed to examine the efficacy of positron emission tomography in fusion with computed tomography (PET-CT) parameters in predicting survival outcomes for patients with malignant pleural mesothelioma. Material and methods. This study retrospectively evaluated the data of 250 patients who were followed up after a diagnosis of malignant pleural mesothelioma. The relationship of pre-treatment [maximum standardized uptake value (SUV max1 ), metabolic tumor volume (MTV1), total lesion glycolysis (TLG1), tumor/background (TBR1), pleural thickness1), post-treatment (SUV max2 , MTV2, TLG2, TBR2, pleural thickness2], and D PET-CT parameters with survival was retrospectively evaluated in 36 patients whose pre-and post-treatment CT scan examinations were complete. Results. The median age of the patients was 57.5 years, ranging from 35 to 76. Median follow-up time was 16 months, with a range of 7 to 42 months. Median survival was calculated as 18.8 months for all patients. Based on the determined cut-off values, overall survival was determined as 29.9 months in patients with TLG2 ≤ 158 compared to 16 months in patients with TLG2 > 158 (p = 0.009) and as 30.9 months in patients with D TLG ≤ –62.58 compared to 16 months in patients with D TLG > –62.58 (p = 0.001). In addition, median overall survival (OS) was determined as 29.9 months in patients with MTV2 ≤ 63.9 compared to 16 months in patients with MTV2 > 63.9 (p = 0.007) and as 29.9 months in patients with D MTV ≤ –54.03 compared to 16 months in patients with D MTV > –54.03 (p = 0.002). When evaluated with respect to TBR2; median OS was 29.9 months in patients with TBR2 ≤ 1.84 compared to 16 months in patients with TBR2 > 1.84 (p = 0.039). Conclusions. Our research findings indicate a correlation between OS and volumetric PET-CT measures, specifically TLG and MTV.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":"3 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology in Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/ocp.2023.0022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. This study aimed to examine the efficacy of positron emission tomography in fusion with computed tomography (PET-CT) parameters in predicting survival outcomes for patients with malignant pleural mesothelioma. Material and methods. This study retrospectively evaluated the data of 250 patients who were followed up after a diagnosis of malignant pleural mesothelioma. The relationship of pre-treatment [maximum standardized uptake value (SUV max1 ), metabolic tumor volume (MTV1), total lesion glycolysis (TLG1), tumor/background (TBR1), pleural thickness1), post-treatment (SUV max2 , MTV2, TLG2, TBR2, pleural thickness2], and D PET-CT parameters with survival was retrospectively evaluated in 36 patients whose pre-and post-treatment CT scan examinations were complete. Results. The median age of the patients was 57.5 years, ranging from 35 to 76. Median follow-up time was 16 months, with a range of 7 to 42 months. Median survival was calculated as 18.8 months for all patients. Based on the determined cut-off values, overall survival was determined as 29.9 months in patients with TLG2 ≤ 158 compared to 16 months in patients with TLG2 > 158 (p = 0.009) and as 30.9 months in patients with D TLG ≤ –62.58 compared to 16 months in patients with D TLG > –62.58 (p = 0.001). In addition, median overall survival (OS) was determined as 29.9 months in patients with MTV2 ≤ 63.9 compared to 16 months in patients with MTV2 > 63.9 (p = 0.007) and as 29.9 months in patients with D MTV ≤ –54.03 compared to 16 months in patients with D MTV > –54.03 (p = 0.002). When evaluated with respect to TBR2; median OS was 29.9 months in patients with TBR2 ≤ 1.84 compared to 16 months in patients with TBR2 > 1.84 (p = 0.039). Conclusions. Our research findings indicate a correlation between OS and volumetric PET-CT measures, specifically TLG and MTV.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗前后18F-FDG PET-CT体积参数变化对胸膜间皮瘤总生存率的影响
介绍。本研究旨在探讨正电子发射断层扫描与计算机断层扫描(PET-CT)参数融合预测恶性胸膜间皮瘤患者生存结果的有效性。材料和方法。本研究回顾性评估了250例诊断为恶性胸膜间皮瘤后随访的患者资料。回顾性评价36例完成治疗前后CT扫描检查的患者治疗前[最大标准化摄取值(SUV max1)、肿瘤代谢体积(MTV1)、病灶总糖解(TLG1)、肿瘤/背景(TBR1)、胸膜厚度1)、治疗后(SUV max2、MTV2、TLG2、TBR2、胸膜厚度2]、D PET-CT参数与生存率的关系。结果。患者的中位年龄为57.5岁,年龄范围为35 - 76岁。中位随访时间为16个月,7 ~ 42个月。所有患者的中位生存期为18.8个月。根据确定的临界值,TLG2≤158的患者总生存期为29.9个月,而TLG2 > 158的患者总生存期为16个月(p = 0.009); D TLG≤-62.58的患者总生存期为30.9个月,而D TLG > -62.58的患者总生存期为16个月(p = 0.001)。此外,MTV2≤63.9的患者的中位总生存期(OS)为29.9个月,MTV2 > 63.9的患者为16个月(p = 0.007); D MTV≤-54.03的患者为29.9个月,D MTV > -54.03的患者为16个月(p = 0.002)。当对TBR2进行评估时;TBR2≤1.84的患者中位OS为29.9个月,而TBR2 > 1.84的患者中位OS为16个月(p = 0.039)。结论。我们的研究结果表明,OS和体积PET-CT测量之间存在相关性,特别是TLG和MTV。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.90
自引率
20.00%
发文量
46
审稿时长
15 weeks
期刊最新文献
Immunochemotherapy in patients with non-squamous lung cancer Chemotherapy in patients with testicular germ-cell tumors and end-stage renal disease requiring hemodialysis: two case reports Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index as clinical predictive and prognostic markers in patients with advanced pancreatic cancer receiving gemcitabine monotherapy Systemic treatment in triple-negative breast cancer patients — standard and novel approaches Tumor heterogeneity and its impact on sotorasib response in a patient with non-small cell lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1